Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 clients • 9 examiners • 5 art units • 0 of 9 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
ArentFox Schiff, LLP & DFCI operates in the Biotechnology & Pharmaceuticals technology area, with 33493 career applications. This massive volume of work demonstrates extensive experience across the patent landscape. The firm is currently managing 8 pending office actions, indicating a focused active workload for this specific partnership.
The firm maintains a resolved allowance rate pct of 88.06, showing a high success rate across its large portfolio. Prosecution typically involves an avg office actions per allowance of 3.27. This average suggests that securing an allowance in Biotechnology & Pharmaceuticals often requires several rounds of negotiation with the USPTO.
The 88.06 resolved allowance rate pct across 33493 career applications underscores the firm's reliability as a large-scale prosecution partner. The 3.27 avg office actions per allowance provides a benchmark for clients expecting a thorough prosecution process. With 8 pending office actions, the firm continues to leverage its vast experience to achieve successful outcomes.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| §102 only | 1 (11%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 3 (33%) |
| Multi-statute (no §101) | 1 (11%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GAUGER, PAUL RANDALL | 1 | 56.0% | +12.1% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| CHICKS, ASHLI ARIANA | 1 | 60.6% | +50.3% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.5% | +49.1% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 13d |
| 18557225 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 13d |
| 18033872 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | ABDALHAMEED, MANAHIL MIRGHANI ALI | 22d |
| 17926074 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | LEE, CHIHYI NMN | 34d |
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | CHICKS, ASHLI ARIANA | 54d |
| 18559655 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | GAUGER, PAUL RANDALL | — |
| 17621057 | HCK DEGRADERS AND USES THEREOF | LADD, CAROLYN LOUISE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| DANA-FARBER CANCER INSTITUTE, INC. | 5 |
| Cornell University | 1 |
| Yeda Research And Devlopment Co. Ltd. | 1 |
| KIST | 1 |
| NEOMORPH, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1622 | 3 |
| 1629 | 2 |
| 1621 | 2 |
| 1626 | 1 |
| 1628 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18559655 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Cornell University | GAUGER, PAUL RANDALL | 1629 | §112 | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18557225 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112DPOther | Final Rejection | — | Pending | Oct 25, 2023 |
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | Yeda Research And Devlopment Co. Ltd. | CHICKS, ASHLI ARIANA | 1626 | §102Other | Non-Final OA | 54d | Pending | Sep 13, 2023 |
| 18033872 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | Korea Institute Of Science And Technology (Kist) | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103 | Non-Final OA | 22d | Pending | Apr 26, 2023 |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Neomorph, Inc. | TOWNSLEY, SARA ELIZABETH | 1629 | §112DP | Non-Final OA | 13d | Pending | Apr 10, 2023 |
| 17926074 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | LEE, CHIHYI NMN | 1628 | §112DP | Final Rejection | 34d | Pending | Nov 17, 2022 |
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112 | Final Rejection | 182d overdue | Pending | Aug 23, 2022 |
| 17621057 | HCK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | LADD, CAROLYN LOUISE | 1622 | DP | Final Rejection | — | Pending | Dec 20, 2021 |
| 17419965 | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS | DANA-FARBER CANCER INSTITUTE, INC. | YOO, SUN JAE | 1621 | — | Final Rejection | 15d overdue | Pending | Jun 30, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial